胞必佳\顺铂腔内注入治疗恶性胸液疗效观察
![]() |
第1页 |
参见附件(1676KB,2页)。
[摘要]目的观察恶性胸液腔内注入胞必佳、顺铂的临床疗效。方法36例晚期癌症并发胸腔积液患者随机分为N-CWS组20例和对照组16例。治疗组腔内注入N-CWS 600ug、DDP 40mg/m2,对照组腔内注入DDP40mg/m2。观察积液控制情况、KPS评分的变化。结果治疗组胸腔积液控制有效率(CR+PR=85%),较对照组有显著差异(P<0.05),KPS评分提高有效率90%,较对照组有非常显著差异(P<0.01)。结论N-CWS、DDP联合腔内注入治疗恶性胸液效果明显,并能明显提高病人生活质量。
[关键词]胸腔积液;胞必佳(N-CWS);顺铂(DDP);治疗
[中图分类号]R730.6[文献标识码]A [文章编号] 1005-0515(2010)-7-003-01
Clinical study of nocardia rubracell wall skeleton(N-CWS)and cisplatin (DDP)in treating m alignant pleural effusion
Bian xiuhua
(Traditional Chinese Medicine Hospital of Jia Xiang Shandong Jia Xiang 272400)
[Abstract]ObjectiveToobserve the treatment of N-CWS、DDP on the patients with m alignant pleural effusion.Methods There were 36 patients with m alignant pleural effusion in the study.36 cases were randomly divided into two groups(N-CWS group and control group).Each case was released the effusion。When therc was on evidence of fluid in the pleural space as assessed by plain chest roentgenography or B-superson.10ml of 2%lidocaine 600ug of-CWS 40ml of saline solution (0.9%)、5mg of DXM and/or 40mg/m2 of DDP Was injected into pleural space。The patients were asked to change。position to allow adequate distribution of medicines.The changes of pleural effitsion were recorded,KSP score was evaluated in both groups.ResultsIn N-CWS group the clinical effects(CR+PR=85%)weremagnificently decreased than control group(x2=5.13),(P<0.05),KPS score was significantly improved(P<0.01)。ConclusionThe treatment of N一CWS、DDP on the patients with m alignant pleural effusion is a effective way.It may improve qualityof life in patients.
[Keywords]norcardia rubraell wall skeleton(N-CWS);pleural effusin;cisplatin(DDP)
胞必佳-红色诺卡氏菌细胞壁骨架(N-CWS)是一种生物反应调节剂,具有理想的抗肿瘤免疫效应。我科应用N-CWS、顺铂(DDP)联合腔内注入治疗恶性胸腔积液病人,疗效明显,报告如下。
1 材料与方法
1.1 病例选择经病理学或细胞学检查证实的36例恶性胸液病人,其中肺腺癌l4例,鳞癌6例,小细胞肺癌8例,胸膜间皮瘤8例。男21例,女15例,年龄30-77岁。复治病人l2例,距上次抗肿瘤治疗至少l月。Kamofsky评分>50分;临床分期:Ⅲb期20例,Ⅳ期l6例。预计生存期3个月以上,无心、肝、肾功能障碍。治疗组20例,对照组l6例。
1.2 治疗方法B超定位后尽量抽尽胸水,将2%利多卡因10ml、N-CWS600ug、生理盐水40ml、DDP 40mg/m2、地塞米松5mg注入胸腔内,拔针后嘱病人缓慢转动体位,以使药液与胸膜接触,每周一次,共2-6次。对照组不用N-CWS,余同治疗组。治疗前后检查B超、血常规、肝、肾功能,并观察病人胸水吸收情况、Kamofsky评分的变化。
1.3 疗效评定胸水疗效评定标准参照Millar标准[1]:完全缓解(CR):胸水完全消失,且稳定4周以上;部分缓解(PR):胸水减少1/2以上维持4周以上;无效(NE):未达到上述指标者。KPS评分,CR:KPS评分增加20分以上;PR:KPS评分增加l0分以上;NE:KPS评分增加小于l0分或不增加 ......
您现在查看是摘要介绍页,详见PDF附件(1676KB,2页)。
闂勬劒绨張宥呭閸c劌甯囬崝娑崇礉缂冩垹鐝柈銊ュ瀻娣団剝浼呴崣顏冪返閻栧崬绺炬导姘喅閹存牗婀佹稉鈧€规氨袧閸掑棛娈戝▔銊ュ斀娴兼艾鎲冲ù浣筋潔閵嗭拷
濮濓拷 pdf閸忋劍鏋� 闂団偓鐟曪拷 5 缁夘垰鍨庨敍鍫濆帳鐠愯鏁為崘宀€娅ヨぐ鏇炴倵濮e繐銇夐崣顖欎簰妫板棗褰�10娑擃亞袧閸掞拷閿涘鈧拷
閺傚洨鐝烽悧鍫熸綀鐏炵偘绨崢鐔绘啿娴f粍娼堟禍鐚寸礉閼汇儲鍋嶇拋銈勮礋濮濄倖鏋冩稉宥呯杹鐞氼偅鏁硅ぐ鏇氱返婢堆冾啀閸忓秷鍨傞梼鍛邦嚢閿涘矁顕柇顔绘閹存牜鏁哥拠婵嬧偓姘辩叀閹存垳婊戦敍灞惧灉娴狀剚鏁归崚浼粹偓姘辩叀閸氬函绱濇导姘辩彌閸楀啿鐨㈤幃銊ф畱娴f粌鎼ф禒搴㈡拱缂冩垹鐝崚鐘绘珟閵嗭拷
瀵邦喕淇婇弬鍥╃彿
閸忚櫕鏁為惂鐐
鐠囧嫯顔戦崙鐘插綖
閹兼粎鍌ㄩ弴鏉戭樋
閹恒劌鐡ㄧ紒娆愭箙閸欙拷
閸旂姴鍙嗛弨鎯版
|